—
1 filing since 2025 · no dollar figures disclosed
Biostax Corp. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products, with a focus on autoimmunity and immune restoration. Its lead investigational candidate is Lodonal, a once-daily immune system regulator being developed for the management of HIV/AIDS in markets outside the United States. The company also holds JKB-122, a small molecule targeting NASH, autoimmune hepatitis and chronic liver disease, and a BiostaxRx inflammaging program based on low-dose naltrexone formulations. Biostax is publicly quoted on the OTC market under the ticker BTAX and was formerly known as Immune Therapeutics, Inc. before its October 2023 rename.
What sets it apart
Biostax focuses on low-dose naltrexone-based immune modulation with a defined path to market in emerging markets — particularly Africa — rather than pursuing a conventional US-first clinical and commercial route.
A once-a-day immune system regulator, an oral low-dose naltrexone formulation, in development for the management of HIV and AIDS in markets outside the United States.
